$VRAX News

Why Is Virax Biolabs (VRAX) Stock Trending Overnight?

What's Behind The Jump In Virax Biolabs Stock?

Virax Biolabs Group shares are trading higher after the company announced that its subsidiary, Virax Biolabs, achieved ISO 13485:2016 and ISO 9001:2015 certification for its quality management system.

Virax Biolabs Group's Subsidiary Secures ISO 13485:2016 And ISO 9001:2015 Certification For Its Quality Management System

Virax Biolabs Group Limited (VRAX) Upgraded to Buy: Here's Why

Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement

Virax Biolabs (VRAX) Stock Cools After Hours Following 75% Rally

Virax Biolabs Group Limited Announces $5 Million Private Placement

Virax Biolabs Announces $5M Ordinary Shares Offering

Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders

Virax Biolabs Group shares are trading higher after the company announced clinical progress and intends to report clinical data from its UK PAIS trial in 2026.

Virax Biolabs Group Shares Clinical Progress, Intends To Report Clinical Data From UK PAIS Trial In 2026

Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes

Virax Biolabs Completes Patient Recruitment For UK-Based, Multi-Centre Clinical Study Evaluating Performance Of ViraxImmune Assay In Detecting T Cell Dysfunction In PAIS, Including Long COVID, PTLD, And ME/CFS

Virax Biolabs (VRAX) Falls 18% on Lack of Leads

Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September

EXCLUSIVE: Virax Biolabs Inks Research Pact To Advance Long COVID Diagnostic Studies

EXCLUSIVE: Virax BioLabs Tells Benzinga Co. Partners With Emory University On ViraxImmune Clinical Studies, Says Readies For FDA Pre-Submission Meeting In Early September

Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy

Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency